Similar Search Results

A comparative analysis of generics markets in five European countries

Garattini, Livio; Tediosi, Fabrizio - In: Health Policy 51 (2000) 3, pp. 149-162

Persistent link: https://www.econbiz.de/10005520452

Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: Health Policy 119 (2015) 2, pp. 212-216

Trastuzumab (TR), a monoclonal antibody approved by EMA in 2000 and one of the first examples of “targeted therapy”, is indicated to treat human epidermal growth factor receptor 2 (HER2) positive breast cancer. TR, whose patent will expire in 2015 in Europe, has been judged positively for...

Persistent link: https://www.econbiz.de/10011190167

Vooren, Katelijne; Curto, Alessandro; Garattini, Livio - In: Applied Health Economics and Health Policy 13 (2015) 2, pp. 125-127

Persistent link: https://www.econbiz.de/10011241533

Could co-payments on drugs help to make EU health care systems less open to political influence?

Garattini, Livio; Vooren, Katelijne - In: The European Journal of Health Economics 14 (2013) 5, pp. 709-713

Persistent link: https://www.econbiz.de/10010698251

Pricing Human Papillomavirus Vaccines

Garattini, Livio; Vooren, Katelijne; Curto, Alessandro - In: PharmacoEconomics 30 (2012) 3, pp. 213-217

Persistent link: https://www.econbiz.de/10010634521

Health technology assessment: for whom the bell tolls?

Garattini, Livio; Casadei, Gianluigi - In: The European Journal of Health Economics 9 (2008) 4, pp. 311-312

Persistent link: https://www.econbiz.de/10005759980